ProQR Therapeutics N.VPRQR
Price$1.63

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $18.7M-4.6% YoYTTM through 31 Dec 2025
Net Income -$49.5MTTM through 31 Dec 2025
Free Cash Flow -$63.2MTTM through 31 Dec 2025

Margins

Current
EBITDA Margin-218.3%
Operating Margin-273.1%
Net Margin-265.2%

Returns

-85.5%ROE
-37.4%ROA

Balance Sheet Health

Debt / Equity0.10x
Current Ratio3.09x
Net Debt-$87.5Mnet cash position
Cash & Equivalents$74.8M

Quality Metrics

Piotroski F-Score0 / 9
FCF Margin-338.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.40

Dividend

No dividend

Capital Allocation

Capex Intensity5.5%

Segment Performance

No segment data available.

Financials converted at 0.8513 from EUR.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.